Johnson & Johnson federal lobbying and pharma policy; drug pricing and tort reform
By 2026, Johnson & Johnson remains one of the largest healthcare lobbyists in Washington, reporting millions in federal lobbying expenditure (OpenSecrets). The company engages on drug pricing (IRA Medicare negotiation), medical device regulation, tort reform, and liability limits linked to talc and other litigation. J&J's use of the "Texas two-step" bankruptcy strategy (LTL Management) to manage talc claims has drawn political and judicial scrutiny. PAC contributions and state lobbying continue to shape policy on pharmaceutical and consumer health regulation.
J&J lobbying on Medicare drug price negotiation and device regulation
In 2025, Johnson & Johnson continued to lobby Congress and federal agencies on Medicare drug price negotiation under the Inflation Reduction Act (IRA), medical device oversight (FDA), and liability and tort reform. The company's talc litigation strategy (including LTL Management bankruptcy proceedings) remained politically contentious. J&J and subsidiary PACs contributed to federal candidates and committees; lobbying disclosure reports listed healthcare, pharmaceuticals, and product liability among top issues.
J&J among top federal lobbyists; IRA drug pricing and talc bankruptcy in spotlight
In 2024, Johnson & Johnson reported over $8 million in federal lobbying (OpenSecrets), among the highest in the pharmaceutical and healthcare sector. Lobbying focused on drug pricing (IRA implementation, Medicare negotiation), FDA regulation, and medical devices. The company's LTL Management bankruptcy filing to resolve talc claims drew criticism from plaintiffs and some lawmakers; the Supreme Court and lower courts continued to weigh the limits of bankruptcy for mass-tort liability. J&J PAC remained a significant donor to federal candidates.
J&J LTL bankruptcy strategy challenged; lobbying on IRA and FDA
In 2023, the Third Circuit dismissed LTL Management's (J&J's talc-liability subsidiary) bankruptcy, ruling it was not in good faith because J&J was not in financial distress. The "Texas two-step" tactic—spinning off liabilities into a new entity that then files for bankruptcy—drew political and legal backlash. J&J continued heavy federal lobbying on drug pricing (IRA Medicare negotiation), FDA issues, and product liability. The company remained a top healthcare lobbyist and PAC contributor.
J&J spins talc liabilities into LTL Management; bankruptcy and political reaction
In 2022, Johnson & Johnson used a "Texas two-step" corporate restructuring: it placed talc-related liabilities into a new entity, LTL Management, which then filed for bankruptcy. The move aimed to resolve tens of thousands of talc claims through a trust while insulating J&J. Critics—including plaintiffs and some members of Congress—argued the tactic abused bankruptcy law. J&J lobbied on healthcare, drug pricing, and liability; federal lobbying spend remained among the highest in pharma. The Inflation Reduction Act (IRA) drug-pricing provisions passed in August 2022, setting up years of industry lobbying on implementation.
J&J creates LTL Management and files for bankruptcy to manage talc claims
In October 2021, Johnson & Johnson announced it had placed its talc-related liabilities into a new subsidiary, LTL Management, which immediately filed for Chapter 11 bankruptcy. The "Texas two-step" move was designed to resolve talc litigation through a proposed trust while keeping J&J's main operations out of bankruptcy. The strategy drew sharp criticism from plaintiffs' lawyers and some legislators and became a focal point for debate over corporate use of bankruptcy to limit mass-tort liability. J&J continued to lobby on drug pricing, FDA, and liability reform.
J&J federal lobbying tops $7M; COVID, drug pricing, and talc litigation
In 2020, Johnson & Johnson reported over $7 million in federal lobbying (OpenSecrets), with issues including healthcare, pharmaceuticals, COVID-19 response (vaccine and therapeutics), drug pricing, and product liability. The company was in the midst of tens of thousands of talc-related lawsuits and had stopped selling talc-based baby powder in the US and Canada. J&J's PAC contributed to federal candidates; the company lobbied on Medicare, Medicaid, FDA regulation, and tort reform. Political spending and lobbying remained central to its strategy on litigation and pricing.
J&J lobbies on drug pricing and opioid legislation; talc trials and political fallout
In 2019, Johnson & Johnson lobbied on federal drug pricing proposals (Congress and Trump administration), opioid legislation, and FDA policy. The company faced mounting talc litigation and an Oklahoma opioid trial where it was found liable (later reversed on appeal). J&J's federal lobbying spend exceeded $6 million; the company and its PAC were major political donors. Healthcare and pharmaceutical industry groups, of which J&J is a key member, fought Medicare negotiation and price controls while supporting voluntary measures.
J&J federal lobbying on tax, drug pricing, and device regulation; opioid and talc scrutiny
In 2018, Johnson & Johnson lobbied on tax policy (TCJA implementation), drug pricing, medical device regulation (FDA), and healthcare reform. The company faced growing opioid and talc litigation; state and federal lawmakers scrutinised pharma's role in the opioid crisis. J&J's lobbying expenditure remained above $6 million; PAC contributions supported incumbents and candidates across parties. The company engaged with Congress on Medicare, Medicaid, and pharmaceutical supply chain issues.
J&J lobbies on ACA repeal, tax reform, and FDA; opioid crisis in political focus
In 2017, Johnson & Johnson lobbied on Affordable Care Act (ACA) repeal and replace efforts, tax reform (Corporate Tax Cuts and Jobs Act), FDA user fees, and drug pricing. The opioid crisis had become a major political issue; J&J and other manufacturers faced state and federal investigations. The company's lobbying spend exceeded $6 million; its PAC was one of the largest in the healthcare sector. Medical device and pharmaceutical regulation remained core lobbying priorities.
J&J election-year lobbying and PAC spending; drug pricing and device regulation
In 2016, Johnson & Johnson reported over $6 million in federal lobbying and significant PAC contributions in a presidential and congressional election year. Lobbying focused on healthcare reform, drug pricing (Congressional hearings and draft legislation), FDA regulation (devices and drugs), and tax policy. J&J was a member of PhRMA and other trade groups that lobbied against price controls and in favour of strong IP and regulatory predictability. Talc litigation was growing; the company defended its products and engaged on tort and liability issues.
J&J lobbying on ACA, FDA, and drug pricing; congressional scrutiny of pharma
In 2015, Johnson & Johnson lobbied on Affordable Care Act implementation, FDA reauthorisation (user fees, device regulation), and drug pricing—a topic that gained traction after high-profile price increases by other companies. Congress held hearings on pharmaceutical pricing and access; J&J and PhRMA argued for value-based pricing and against government price controls. Federal lobbying spend remained above $5 million; PAC donations supported both parties. Medical device tax (ACA) repeal was a priority for device makers including J&J.
J&J federal lobbying on ACA, FDA, and medical device tax; midterm elections
In 2014, Johnson & Johnson lobbied on ACA implementation (including medical device excise tax repeal), FDA regulation, and healthcare programmes. The company's federal lobbying expenditure was over $5 million; J&J PAC contributed to congressional candidates in the midterms. Device makers, including J&J's medical technology segment, sought repeal of the 2.3% device tax. Drug pricing and Medicare Part D were also on the lobbying agenda as policymakers debated cost and access.
J&J lobbies on ACA implementation, device tax, and FDA; government healthcare programmes
In 2013, Johnson & Johnson engaged heavily on Affordable Care Act implementation, including the medical device excise tax that took effect in January. The company and industry groups lobbied for repeal or delay of the tax. FDA reauthorisation (PDUFA, MDUFA), drug and device approval pathways, and Medicare/Medicaid policy were other priorities. J&J's lobbying spend exceeded $5 million; the company was a leading voice for the pharmaceutical and device industries in Washington.
J&J election-year lobbying; ACA, device tax, and FDA; Supreme Court and healthcare
In 2012, Johnson & Johnson lobbied on the Affordable Care Act (upheld by the Supreme Court in June), including the impending medical device tax. FDA user-fee reauthorisation (PDUFA V) passed; J&J and industry supported the legislation. Federal lobbying spend was over $5 million; PAC contributions were significant in the presidential and congressional elections. Healthcare reform, Medicare, Medicaid, and pharmaceutical regulation remained at the centre of the company's political engagement.
J&J lobbies on ACA implementation and device tax; FDA and healthcare reform
In 2011, Johnson & Johnson lobbied on implementation of the Affordable Care Act, including efforts to repeal or modify the medical device excise tax (scheduled for 2013). FDA regulation, drug and device approval pathways, and Medicare/Medicaid policy were priorities. The company's federal lobbying expenditure was over $6 million. J&J participated in PhRMA and AdvaMed (device association) advocacy; industry sought to shape healthcare rules and protect intellectual property and pricing flexibility.
J&J lobbies on ACA passage and implementation; healthcare reform and FDA
In 2010, Johnson & Johnson was deeply engaged in the debate over the Affordable Care Act, which was signed in March. The company and PhRMA had negotiated with the Obama administration on Medicare Part D and other provisions; the final law included a medical device excise tax that J&J and AdvaMed would later lobby to repeal. Federal lobbying spend exceeded $6 million. FDA regulation, drug safety, and healthcare programmes remained core issues. The midterm elections saw heavy industry PAC activity.
J&J and PhRMA negotiate with White House on healthcare reform; drug pricing and Medicare
In 2009, Johnson & Johnson and PhRMA negotiated with the Obama administration on healthcare reform. PhRMA agreed to support the legislation in exchange for limits on Medicare drug price negotiation and other concessions. J&J's federal lobbying spend was over $6.5 million, among the highest in the sector. The company lobbied on Medicare Part D, FDA regulation, and medical device policy. Healthcare reform dominated the political agenda and defined J&J's lobbying priorities for the year.
J&J lobbies on Medicare Part D, FDA, and drug safety; PDUFA reauthorisation
In 2007, Johnson & Johnson lobbied on PDUFA reauthorisation (Prescription Drug User Fee Act), FDA drug safety and device regulation, and Medicare Part D. The company's federal lobbying expenditure was over $5 million. Congress held hearings on drug safety and industry influence; J&J engaged on transparency and post-market surveillance. Medical device regulation and reimbursement were also priorities. The company was a major PAC donor and active in state and federal healthcare policy.
Johnson & Johnson political influence at the turn of the millennium
By 2000, Johnson & Johnson was already one of the world's largest healthcare companies (pharmaceuticals, medical devices, consumer health) and a significant political actor in the United States. The company lobbied on FDA regulation, Medicare and Medicaid, drug pricing, and product liability. Federal lobbying disclosure (LDA) had been in place since 1995; J&J's reported spending was in the millions. The following decade would bring Medicare Part D (2003/2006), healthcare reform (2009–2010), and rising scrutiny of pharma lobbying and pricing—with J&J consistently among the top spenders and PAC contributors in the sector.
J&J workforce and labor relations; post-Kenvue split and supply chain labor
By 2026, Johnson & Johnson (pharmaceuticals and MedTech) and Kenvue (consumer health, spun off 2023) operate as separate employers. J&J continues to face scrutiny on supply chain labor (contract manufacturing in India, China, and elsewhere), workplace safety, and unionization efforts at some US and international sites. The company reports on human rights and responsible sourcing in its sustainability and citizenship reports. Labor disputes, wage campaigns, and OSHA or equivalent oversight remain part of the sector landscape for large healthcare employers.
J&J and Kenvue labor footprint; layoffs and restructuring in pharma and consumer
In 2025, Johnson & Johnson and Kenvue each managed their own labor relations following the 2023 spin-off. Both companies had announced restructuring and layoffs in prior years (J&J in MedTech and R&D; Kenvue in consumer health). Union organizing and collective bargaining at manufacturing and distribution sites in the US and abroad continued to be reported. J&J's commitment to diversity, inclusion, and safe workplaces was communicated in corporate reporting alongside ongoing labor and supply-chain due diligence.
J&J announces layoffs in MedTech and R&D; union and worker response
In 2024, Johnson & Johnson announced layoffs affecting its MedTech and pharmaceutical R&D operations as part of cost-cutting and portfolio prioritisation. The company had completed the separation of Kenvue (consumer health) in 2023, which also involved workforce transitions. Unions and worker advocates raised concerns about job security and outsourcing. J&J continued to report on employee engagement, safety, and diversity; labor relations at unionised sites (e.g. some US plants) and at contract manufacturers remained in focus for NGOs and investors.
J&J completes Kenvue spin-off; workforce split and consumer health labor
In 2023, Johnson & Johnson completed the spin-off of its consumer health business as Kenvue, creating a separate publicly traded company. The separation involved significant workforce transitions: tens of thousands of employees moved to Kenvue (Tylenol, Listerine, Neutrogena, etc.), while J&J retained pharmaceuticals and MedTech. Labor unions and employee groups monitored the split for impacts on benefits, pensions, and job security. J&J and Kenvue each assumed responsibility for their respective labor relations and HR policies.
J&J plans Kenvue separation; workforce communication and union concerns
In 2022, Johnson & Johnson advanced plans to separate its consumer health business (later Kenvue). The company communicated with employees and unions about the implications for jobs, benefits, and works councils (e.g. in the EU). Labor representatives sought assurances on no forced redundancies and protection of collective agreements. J&J continued to report on safety, diversity, and human rights in its supply chain; contract manufacturing labor conditions in India and other markets remained under scrutiny from advocates and investors.
J&J COVID-19 vaccine production and plant workforce; overtime and safety
In 2021, Johnson & Johnson ramped up production of its COVID-19 vaccine at plants in the US (including the troubled Baltimore Emergent BioSolutions facility that had to be repurposed) and elsewhere. Workforce issues included overtime, shift flexibility, and workplace safety during the pandemic. The company offered paid leave and health measures for employees; unions and workers raised concerns about pressure and safety at high-volume manufacturing sites. J&J's human rights and labor reporting continued to cover supply chain and direct operations.
J&J pandemic response and workforce; remote work, frontline safety, and layoffs
In 2020, Johnson & Johnson responded to the COVID-19 pandemic with remote work for office staff, enhanced safety measures at manufacturing and R&D sites, and accelerated vaccine development. The company announced some layoffs and restructuring in consumer health and other segments as part of cost initiatives. Labor groups and employees raised concerns about exposure risks for frontline workers and about job security. J&J reported on employee wellbeing and diversity; supply chain labor (e.g. in India) remained a focus for human rights assessments.
J&J supply chain labor and human rights; India and emerging markets
In 2019, Johnson & Johnson faced continued scrutiny on supply chain labor and human rights. Reports and NGOs highlighted conditions at contract manufacturers in India and other emerging markets where J&J sources or manufactures. The company's responsible sourcing and human rights policies were updated; audits and remediation were reported in sustainability materials. In the US and EU, J&J dealt with union negotiations, works councils, and diversity and inclusion initiatives. Labor remained a material topic for ESG and investor engagement.
J&J workplace diversity and inclusion; EEOC and labor compliance
In 2018, Johnson & Johnson promoted diversity and inclusion as a strategic priority and reported on representation, pay equity, and inclusive leadership. The company remained subject to EEOC and similar oversight; discrimination or harassment complaints and settlements were reported in the media. Labor relations at unionised facilities (e.g. certain US manufacturing plants) involved collective bargaining and occasional disputes. J&J's global workforce of over 130,000 (at the time) made labor and HR practices a significant focus for regulators and advocates.
J&J restructuring and job cuts in consumer and pharma; union and political response
In 2017, Johnson & Johnson announced restructuring and job cuts in consumer health and certain pharmaceutical operations. The company cited portfolio optimisation and cost efficiency; unions and affected workers raised concerns about offshoring and plant closures. In the US, some facilities were unionised (e.g. IAM, USW); collective bargaining and plant-level labor relations continued. J&J's global labor footprint included manufacturing in the US, Europe, Latin America, and Asia; labor standards and supplier audits were part of the company's sustainability reporting.
J&J labor relations and plant closures; US and international workforce
In 2016, Johnson & Johnson continued to manage a large global workforce across pharmaceuticals, medical devices, and consumer health. The company announced or completed plant closures and consolidations in the US and abroad, leading to job losses and union pushback in some locations. Labor relations at unionised sites involved wage and benefit negotiations; non-union sites faced occasional organizing campaigns. J&J's human rights policy and supplier standards addressed labor conditions in the supply chain; audits in India and other markets were reported.
J&J wage and hour compliance; overtime and classification disputes
In 2015, Johnson & Johnson faced wage and hour litigation and regulatory scrutiny in the US, including claims related to overtime, classification of employees (exempt vs. non-exempt), and rest breaks. The company settled or defended such cases as part of broader labor and employment risk. J&J continued to report on fair labor practices and employee benefits; union negotiations at manufacturing sites addressed wages and working conditions. Global supply chain labor (e.g. raw materials, contract manufacturing) remained in scope for human rights due diligence.
J&J OSHA and workplace safety; manufacturing and R&D sites
In 2014, Johnson & Johnson operated manufacturing and R&D facilities subject to OSHA (US) and equivalent workplace safety regimes abroad. The company reported on safety metrics (recordable incidents, lost-time rates) in sustainability and internal reporting. Inspections and occasional citations occurred at plant level; J&J emphasised a culture of safety and training. Labor unions and worker advocates raised concerns about chemical exposure, ergonomics, and contractor safety at some sites. Supply chain labor conditions, including in India, were part of human rights and ESG reporting.
J&J labor and restructuring in consumer health; job cuts and site closures
In 2013, Johnson & Johnson continued restructuring in its consumer health segment, including job cuts and site rationalisation. The company had faced quality and recall issues at some plants (e.g. McNeil Consumer Healthcare); consolidation and remediation affected workforce levels. Unions and local officials in affected regions (e.g. US, Europe) responded to announcements of closures or layoffs. J&J's global labor relations included works councils in the EU and collective bargaining where unions were recognised. Human rights and supply chain labor remained on the corporate agenda.
J&J discrimination and harassment claims; EEOC and workplace culture
In 2012, Johnson & Johnson faced discrimination and harassment complaints and litigation in the US and elsewhere. EEOC charges and private lawsuits alleged gender, race, or age discrimination; some cases were settled. The company promoted diversity and inclusion initiatives and updated policies; labor and employment counsel handled claims and compliance. Unionised sites dealt with grievances and collective bargaining. J&J's large, global workforce made labor and employment practices a recurring area of legal and reputational risk.
J&J plant closures and layoffs; quality issues and workforce impact
In 2011, Johnson & Johnson continued to address quality failures at McNeil Consumer Healthcare plants (recalls of Tylenol and other products), which led to plant shutdowns, remediation, and layoffs. The Fort Washington, Pennsylvania, facility was closed; other sites were consolidated. Unions and workers were affected by the restructuring. J&J's labor relations in the US and internationally included negotiations with unions (e.g. IAM, USW) and compliance with works council requirements in Europe. The company reported on employee engagement and safety.
J&J McNeil recalls and plant shutdowns; workforce and union response
In 2010, Johnson & Johnson's McNeil Consumer Healthcare unit faced major recalls and regulatory action (FDA consent decree later), leading to extended shutdowns at the Fort Washington plant and others. Hundreds of workers were laid off or reassigned; unions (e.g. United Steelworkers) represented affected employees and negotiated severance and transfer rights. The labor impact of the quality crisis was significant in the Philadelphia area and elsewhere. J&J's broader workforce (pharma, devices) continued to be subject to collective bargaining and labor law in multiple countries.
J&J recession-era layoffs and cost cuts; global workforce restructuring
In 2009, Johnson & Johnson announced layoffs and cost-cutting measures in response to the global recession and patent expiries. The company cut thousands of jobs across pharmaceuticals, devices, and consumer health; unions and works councils were consulted in the EU and elsewhere. Plant closures and consolidation affected US and European sites. J&J's labor relations included negotiations on severance, retraining, and redeployment. The company remained one of the world's largest healthcare employers, with labor practices under scrutiny from investors and NGOs.
J&J union negotiations and plant-level labor relations; US and EU
In 2007, Johnson & Johnson engaged in collective bargaining with unions at various US plants (e.g. IAM, USW) and with works councils in Europe. Wage increases, benefits, and job security were typical issues. The company also continued to expand or consolidate manufacturing globally; some sites were closed or sold, affecting jobs. J&J's labor and human resources policies addressed diversity, safety, and fair treatment; the company was periodically subject to NLRB proceedings and labor disputes. Supply chain labor in emerging markets gained attention in corporate responsibility reporting.
Johnson & Johnson labor and workforce at the turn of the millennium
By 2000, Johnson & Johnson employed over 98,000 people worldwide across pharmaceuticals, medical devices, and consumer products. The company had unionised plants in the US (e.g. IAM, USW) and works councils in Europe; labor relations were a routine part of operations. J&J promoted its Credo and culture of care for employees; workplace safety, benefits, and diversity were emphasised. The following decades would bring restructuring, layoffs, quality crises (McNeil), supply chain labor scrutiny, the Kenvue spin-off, and continued union and regulatory engagement—making labor a persistent theme in J&J's corporate story.
J&J and Kenvue recall landscape; consumer health and device vigilance
By 2026, Johnson & Johnson (pharma and MedTech) and Kenvue (consumer health, spun off 2023) each manage their own recall and quality systems. J&J's pharmaceutical and device divisions remain subject to FDA and international recall rules; Kenvue handles Tylenol, Listerine, Neutrogena, and other consumer brands. Past recalls—Tylenol/McNeil (2009–2011), sunscreen benzene (2021), hip implants (2010), mesh—remain part of the company's recall history. Both entities maintain recall procedures and regulatory engagement.
J&J and Kenvue recall readiness; FDA and global regulatory context
In 2025, Johnson & Johnson and Kenvue continued to operate under strict FDA and international recall and quality regulations. No single major J&J or Kenvue recall dominated headlines; both companies maintained recall procedures for drugs, devices, and consumer products. Historical issues—McNeil consent decree (ended 2021), sunscreen benzene (2021), hip and mesh devices—informed ongoing quality and supply chain controls. Recall and adverse event reporting remained core to compliance.
J&J and Kenvue product recalls; device and consumer health alerts
In 2024, Johnson & Johnson (pharma, MedTech) and Kenvue (consumer health) each issued or were subject to product recalls and FDA alerts as needed. J&J's medical device business (e.g. orthopaedics, surgery) and Kenvue's over-the-counter and skin-care brands remained under routine surveillance. The companies' recall histories—including McNeil, sunscreen, and devices—kept quality and supply chain management in focus for regulators and investors.
Kenvue assumes consumer health recall responsibility post–J&J split
In 2023, Kenvue (spun off from J&J) became responsible for recall and quality of consumer health brands (Tylenol, Motrin, Listerine, Neutrogena, Aveeno, etc.). Johnson & Johnson retained pharma and MedTech recall obligations. Any consumer-product recalls from August 2023 onward were handled by Kenvue; J&J continued to manage drug and device recalls. The split clarified regulatory and recall ownership while both companies maintained robust quality and recall procedures.
J&J consumer health recalls; FDA and quality systems pre-Kenvue
In 2022, Johnson & Johnson remained responsible for consumer health product recalls ahead of the Kenvue spin-off (2023). The company had exited the FDA consent decree covering McNeil Consumer Healthcare in 2021 after years of remediation. Recalls and market withdrawals for OTC drugs, skin care, or other consumer items were reported to the FDA as required. J&J's pharmaceutical and medical device divisions also maintained recall procedures for drugs and devices.
J&J sunscreen benzene recall; FDA ends McNeil consent decree
In 2021, Johnson & Johnson had two major recall-related events. In July, J&J voluntarily recalled several Neutrogena and Aveeno aerosol sunscreens after testing detected benzene; the FDA posted the recall. In March, the FDA and J&J agreed to end the McNeil consent decree (in place since 2011) after the company achieved sustained compliance. The decree had followed years of Tylenol and other OTC recalls. The sunscreen brands later moved to Kenvue (2023).
J&J consumer health recalls and McNeil compliance under consent decree
In 2020, Johnson & Johnson continued to operate McNeil Consumer Healthcare under the FDA consent decree, with ongoing quality monitoring and remediation. Isolated recalls of consumer products (e.g. specific OTC or skin-care items) were reported to the FDA as required. J&J's pharmaceutical and medical device businesses also managed recall and adverse event reporting. The consent decree would be terminated in March 2021 after the FDA confirmed sustained compliance.
J&J recalls baby powder in US after FDA finds asbestos in single sample
In October 2019, Johnson & Johnson recalled a single lot of Johnson's Baby Powder in the US after the FDA reported finding asbestos in one sample during testing. J&J stated that thousands of tests over decades had shown the product to be safe and asbestos-free and that the recall was undertaken out of an abundance of caution. The incident intensified the long-running talc litigation and controversy. In 2020, J&J announced it would stop selling talc-based baby powder in the US and Canada.
J&J consumer and device recalls; McNeil under consent decree
In 2018, Johnson & Johnson continued to operate McNeil under the FDA consent decree, with ongoing quality systems and audits. The company issued or was associated with recalls of specific consumer or device products as needed; no single recall matched the scale of the 2009–2011 McNeil crisis. J&J's hip implant (Pinnacle) and mesh litigation continued; device recalls and market withdrawals were part of the company's regulatory history. Recall procedures and post-market surveillance remained central to J&J's compliance.
J&J McNeil consent decree compliance; consumer and device recall activity
In 2017, Johnson & Johnson continued to comply with the McNeil consent decree, investing in plant upgrades and quality controls. Isolated recalls of OTC or consumer products were reported. The company's medical device segment (e.g. orthopaedics, surgery) managed device recalls and FDA reporting as required. The legacy of the 2009–2011 Tylenol and children's medicine recalls and the 2011 consent decree shaped J&J's approach to consumer health quality for years.
J&J Hip Solutions recalls optional acetabular cup; Pinnacle litigation continues
In 2016, Johnson & Johnson subsidiary DePuy Synthes (now part of J&J MedTech) announced a voluntary recall of certain Hip Solutions optional acetabular cup components due to higher-than-expected revision rates. The Pinnacle hip implant litigation (metal-on-metal and other configurations) continued; J&J had previously recalled the ASR hip in 2010. The 2016 recall was part of the company's post-market surveillance and device safety efforts. McNeil remained under the FDA consent decree.
J&J McNeil under consent decree; consumer and device recall reporting
In 2015, Johnson & Johnson continued to operate McNeil Consumer Healthcare under the 2011 FDA consent decree. The company worked to bring all McNeil facilities into full compliance; Fort Washington remained closed. Recalls of specific OTC or consumer products were reported as required. J&J's medical device business (DePuy, Ethicon, etc.) managed device recalls and FDA adverse event reporting. The consent decree would remain in effect until 2021.
J&J McNeil remediation and consent decree; ongoing consumer recalls
In 2014, Johnson & Johnson continued remediation at McNeil plants under the FDA consent decree. The company recalled additional consumer products when quality issues were identified; the scale was smaller than the 2009–2011 crisis. J&J invested in manufacturing and quality systems to satisfy the decree and restore confidence. Device recalls (e.g. specific lots or components) were reported to the FDA. The Fort Washington plant remained closed; production had been shifted to other sites.
J&J McNeil consent decree in force; Tylenol, Motrin, and other recalls continue
In 2013, Johnson & Johnson operated McNeil under the 2011 consent decree, with third-party audits and FDA oversight. The company continued to recall specific batches of Tylenol, Motrin, Benadryl, Zyrtec, and other products when quality or contamination issues arose. The decree required McNeil to meet strict manufacturing and testing standards before reopening or expanding production. J&J's device business also managed recalls and FDA reporting. The consumer health quality crisis remained a major operational and reputational focus.
J&J McNeil under consent decree; ongoing consumer product recalls
In 2012, Johnson & Johnson operated McNeil Consumer Healthcare under the FDA consent decree signed in 2011. The company recalled additional OTC products (Tylenol, Motrin, Benadryl, etc.) as quality issues were identified. The decree required remediation at multiple plants and third-party certification before the FDA would release facilities. J&J's hip implant (Pinnacle) and vaginal mesh litigation continued; device recalls and warnings were part of the regulatory landscape. Consumer health quality remained under intense scrutiny.
J&J McNeil signs FDA consent decree; Fort Washington plant closed
In March 2011, Johnson & Johnson and the FDA entered a consent decree covering McNeil Consumer Healthcare. The decree required McNeil to remedy manufacturing violations at its plants (including Fort Washington, Pennsylvania, which was closed), submit to third-party audits, and obtain FDA approval before resuming production of certain products. The decree followed years of recalls (Tylenol, Motrin, Benadryl, Zyrtec, children's medicines) due to quality failures, musty odours, and contamination. The agreement shaped J&J's consumer health operations for a decade.
In 2010, Johnson & Johnson had two major recalls. In August, DePuy (J&J) voluntarily recalled its ASR hip implant systems worldwide due to high revision rates and complications; the recall led to massive litigation. In April–May, J&J expanded a massive recall of Tylenol, Motrin, Benadryl, Zyrtec, and children's medicines due to musty odours and quality issues at McNeil's Fort Washington plant. The FDA criticised McNeil; the crisis led to the 2011 consent decree and plant closure.
J&J McNeil recalls Tylenol and other OTC drugs; musty odour and bacteria
In September 2009, Johnson & Johnson's McNeil Consumer Healthcare unit began a series of recalls of Tylenol, Motrin, Benadryl, and other over-the-counter medicines. The recalls were prompted by consumer reports of a musty or mouldy odour and by the discovery of a chemical (2,4,6-tribromoanisole, TBA) linked to wood pallet packaging, as well as bacterial contamination in some products. The recalls expanded in 2010 and led to FDA inspection, congressional scrutiny, and eventually the 2011 consent decree. The crisis damaged trust in J&J's consumer health quality.
J&J recalls contact lenses and consumer products; device and OTC vigilance
In 2007, Johnson & Johnson issued recalls of certain contact lenses (Acuvue and other brands) and of selected consumer health products due to quality or contamination concerns. The company's recall and quality systems for pharmaceuticals, medical devices, and consumer products were well established; individual recalls were reported to the FDA and other regulators. The scale of recalls was modest compared to the major McNeil crisis that would begin in 2009. J&J's device business (e.g. DePuy) continued to monitor hip and other implant performance.
Johnson & Johnson recall and quality context at the turn of the millennium
By 2000, Johnson & Johnson was a global leader in pharmaceuticals, medical devices, and consumer health (Tylenol, Motrin, Band-Aid, Johnson's Baby Powder, Acuvue, etc.). The company had a long history of product stewardship and recall procedures; the 1982 Tylenol tampering crisis had shaped industry and J&J's approach to crisis management. In the following decade, J&J would face the major McNeil quality crisis (2009–2011), the ASR hip recall (2010), sunscreen benzene (2021), and talc controversy—making recalls a defining part of J&J's modern history alongside its Credo and reputation.
By 2026, Johnson & Johnson aims to have resolved or substantially settled talc ovarian-cancer claims via the LTL Management prepackaged bankruptcy or successor plan, following the $6.48 billion settlement framework. The company continues to face or settle remaining mesh, hip, and pharmaceutical litigation. Federal and state lobbying on tort reform and liability caps remains a priority. J&J's litigation strategy—including use of bankruptcy subsidiaries—has drawn lasting political and judicial scrutiny.
J&J LTL re-files Chapter 11; $6.48B talc settlement vote and opposition
In 2025, Johnson & Johnson's subsidiary LTL Management re-filed for Chapter 11 after the Third Circuit dismissed its second bankruptcy. The company pursued a prepackaged plan tied to its proposed $6.48 billion settlement of ovarian cancer talc claims, with a claimant vote requirement. Some plaintiffs and state AGs opposed the strategy as an abuse of bankruptcy. Talc trials and appeals continued in state and federal courts. Opioid and other product-liability cases remained on the docket.
J&J proposes $6.48B talc settlement; Third Circuit affirms LTL dismissal
In 2024, Johnson & Johnson announced a plan for LTL Management to resolve current and future ovarian cancer talc claims through a consensual prepackaged reorganization, with a proposed present value of about $6.48 billion over 25 years. The plan required a 75% claimant vote before a new bankruptcy filing. The Third Circuit affirmed the dismissal of LTL's second Chapter 11 petition, ruling the subsidiary was not in financial distress. Talc trials and appeals continued; the settlement framework drew support from many plaintiff attorneys and opposition from others.
Third Circuit dismisses LTL Management bankruptcy; talc trials continue
In July 2023, the U.S. Court of Appeals for the Third Circuit dismissed LTL Management's (J&J's talc-liability subsidiary) Chapter 11 bankruptcy, ruling it was not filed in good faith because Johnson & Johnson was not in financial distress. The "Texas two-step" tactic—spinning off talc liabilities into a new entity that then files for bankruptcy—was rejected. Talc trials resumed in state courts; some resulted in plaintiff verdicts. J&J continued to face mesh, hip, and pharmaceutical litigation alongside the talc docket.
J&J LTL bankruptcy litigation; talc and mesh verdicts
In 2022, Johnson & Johnson and its talc subsidiary LTL Management remained in bankruptcy court; plaintiffs and some states challenged the filing. Talc trials in state courts produced mixed verdicts; appellate courts weighed in on punitive damages and consolidation. Ethicon vaginal mesh and Pinnacle hip litigation continued with trials and settlements. The company set aside billions for litigation; the talc bankruptcy strategy remained central to J&J's approach to mass tort resolution.
J&J spins off talc liabilities into LTL Management; first bankruptcy filing
In October 2021, Johnson & Johnson used a "Texas two-step" strategy: it created LTL Management LLC, transferred talc liabilities to it, and LTL immediately filed for Chapter 11 bankruptcy. The move halted talc trials and aimed to force resolution through a trust. Plaintiffs and several state attorneys general opposed the tactic as an abuse of bankruptcy. Courts would later dismiss LTL's petition. Meanwhile, talc verdicts (including reversals and reductions) and mesh/hip litigation continued to shape J&J's liability exposure.
Talc verdicts and appeals; J&J discontinues talc-based baby powder in US and Canada
In 2020, Johnson & Johnson faced ongoing talc verdicts and appeals; some large punitive awards were reduced or overturned on appeal. In May, J&J announced it would stop selling talc-based Johnson's Baby Powder in the US and Canada, citing declining demand and litigation; the company maintained the product was safe. Mesh and Pinnacle hip litigation continued with trials and settlements. The scale of talc claims prompted J&J to explore bankruptcy-based resolution strategies that would materialise in 2021.
Major talc verdicts; $4.7B St. Louis verdict reduced on appeal; FDA finds asbestos in baby powder
In 2019, Johnson & Johnson lost a $4.7 billion verdict in St. Louis (22 plaintiffs; ovarian cancer and mesothelioma); the trial court later reduced punitive damages and the verdict was partly upheld and partly reversed on appeal. The FDA reported finding asbestos in one sample of Johnson's Baby Powder, prompting a limited recall and fuelling litigation. Thousands of talc cases were pending; mesh and Pinnacle hip trials and settlements continued. J&J maintained that its talc was safe and asbestos-free.
Talc and mesh verdicts; $4.7B St. Louis talc trial; Pinnacle hip appeals
In 2018, a St. Louis jury awarded $4.69 billion in compensatory and punitive damages to 22 women who alleged J&J's talc caused ovarian cancer; the company appealed. Ethicon vaginal mesh cases went to trial in multiple states with mixed results. DePuy Pinnacle hip litigation continued with significant verdicts and appeals; the company challenged multidistrict litigation procedures and damages. J&J faced one of the largest product-liability dockets in the US and set aside substantial litigation reserves.
Talc, mesh, and Pinnacle hip trials; multiple plaintiff verdicts
In 2017, Johnson & Johnson faced a wave of talc trials; some resulted in large plaintiff verdicts (later reduced or reversed on appeal). Ethicon pelvic mesh litigation produced trials and settlements. DePuy Pinnacle metal-on-metal hip cases went to trial with multi-million-dollar verdicts; J&J and DePuy appealed. The company continued to defend the safety of talc and its hip and mesh products while negotiating or litigating thousands of claims. Risperdal and other drug litigation also continued.
$72M talc verdict in St. Louis; mesh and Pinnacle hip litigation grows
In February 2016, a St. Louis jury awarded $72 million to the family of a woman who died of ovarian cancer allegedly linked to J&J talc (later reversed on jurisdictional grounds). Talc litigation expanded rapidly; thousands of cases were filed. Ethicon vaginal mesh and DePuy Pinnacle hip trials continued with plaintiff verdicts. J&J defended the safety of its products and challenged jurisdiction, consolidation, and damages in appellate courts. The combined litigation burden became a major corporate focus.
Talc litigation surges; mesh and Pinnacle hip trials; Risperdal verdicts
In 2015, Johnson & Johnson faced a sharp increase in talc lawsuits alleging ovarian cancer and mesothelioma; early trials produced plaintiff verdicts. Ethicon pelvic mesh litigation proceeded with bellwether trials and settlements. DePuy Pinnacle metal-on-metal hip cases were tried with mixed outcomes. Risperdal (antipsychotic) litigation produced verdicts for plaintiffs who alleged J&J failed to warn of gynecomastia and other side effects. The company defended science and labelling and appealed adverse verdicts.
DePuy ASR settlement; mesh and talc litigation momentum
In 2014, Johnson & Johnson and DePuy continued to implement the $2.5 billionASR hip settlement (announced in late 2013) for eligible revision patients. Ethicon vaginal mesh litigation moved forward with trials and settlement discussions. Talc ovarian-cancer litigation gained momentum with new filings and early trial activity. The company faced growing mass-tort dockets across devices and consumer products and increased litigation reserves and defence costs.
DePuy announces $2.5B ASR hip settlement; first major mesh verdict ($3.35M)
In November 2013, DePuy (J&J) announced a U.S. settlement of approximately $2.5 billion to compensate eligible ASR hip implant patients who had revision surgery. In February, a New Jersey jury awarded $3.35 million to a plaintiff in the first Ethicon vaginal mesh case to go to trial (Gross v. Ethicon); the jury found failure to warn and misrepresentation. Mesh and ASR litigation dominated J&J's product-liability landscape; talc cases were beginning to be filed in larger numbers.
Pinnacle hip and vaginal mesh trials; J&J stops selling some mesh products
In 2012, Johnson & Johnson faced trials in DePuy Pinnacle metal-on-metal hip and Ethicon vaginal mesh litigation. In August, J&J's Ethicon unit announced it would stop selling four vaginal mesh products in the U.S., including Gynecare Prolift, citing commercial reasons; plaintiffs alleged the devices caused serious injury. Pinnacle cases (unlike the recalled ASR) continued to be tried. The company defended device safety and faced a growing number of consolidated and individual lawsuits in federal and state courts.
ASR hip and vaginal mesh litigation escalates; Risperdal cases filed
In 2011, Johnson & Johnson faced thousands of DePuy ASR hip lawsuits following the 2010 recall; the first bellwether was settled ahead of trial. Ethicon vaginal mesh litigation expanded as women alleged injury from Prolift and other devices. Risperdal (antipsychotic) litigation grew with claims that J&J failed to warn of male breast growth (gynecomastia) and marketed off-label. The company entered into the McNeil consent decree with the FDA for consumer health quality. Litigation reserves increased significantly.
DePuy ASR hip recall triggers mass litigation; first lawsuits consolidated
Following the August 2010 voluntary recall of the DePuy ASR hip system, Johnson & Johnson and DePuy faced an immediate wave of lawsuits. The first U.S. ASR suit had been filed in June 2010; by December, the Judicial Panel on Multidistrict Litigation consolidated federal ASR cases in the Northern District of Ohio. Plaintiffs alleged the company knew the device had high failure rates but continued to market it. Thousands of cases would follow; vaginal mesh and drug litigation also continued to grow.
Vaginal mesh and ASR hip litigation begins; Risperdal investigations
In 2009, Johnson & Johnson and Ethicon faced early vaginal mesh lawsuits as women alleged injury from pelvic mesh implants. DePuy ASR hip failure data were emerging; the recall would follow in 2010. Risperdal (risperidone) faced government investigations and civil suits over marketing and safety. The company also dealt with the McNeil/Tylenol recall crisis. Litigation across devices and pharmaceuticals began to form the mass-tort landscape that would define the next decade.
Risperdal and drug marketing suits; early device litigation
In 2008, Johnson & Johnson faced Risperdal (risperidone) litigation and government probes into off-label marketing and safety. Subsidiary Janssen and the company would later settle federal and state claims. Early product-liability cases involving vaginal mesh and orthopaedic devices were filed. The company defended its marketing practices and product safety. Broader device and drug litigation would escalate after the DePuy ASR recall (2010) and mesh verdicts (2012–2013).
Risperdal and drug litigation; government investigations into J&J subsidiaries
In 2007, Johnson & Johnson and its subsidiaries faced Risperdal (risperidone) litigation and federal and state investigations into antipsychotic marketing and alleged off-label promotion. Civil and criminal probes would lead to later settlements. Early product-liability claims involving orthopaedic and women's health devices were in development. The 1982 Tylenol tampering episode remained a reference point for crisis management; the coming decade would bring ASR hip, mesh, talc, and broader drug litigation that would reshape J&J's legal profile.
J&J climate and sustainability; net zero 2045 and supplier targets
By 2026, Johnson & Johnson aims to have met or be on track for its 100% renewable electricity goal (achieved in US, Canada, and Europe by 2023) and progress toward 44% Scope 1 & 2 emissions reduction by 2030 (2021 baseline). The company's net zero by 2045 ambition and supplier science-based targets (80% by 2028) drive decarbonisation across pharma, MedTech, and consumer health. Packaging (recyclable/reusable/compostable), water stewardship, and pharmaceuticals-in-the-environment remain part of J&J's environmental reporting and scrutiny from investors and NGOs.
J&J 100% renewable electricity target; packaging and product sustainability
In 2025, Johnson & Johnson targets 100% renewable electricity globally (already achieved in US, Canada, Europe by 2023). The company reports on Scope 1, 2, and 3 emissions and supplier engagement (Onward, Energize, Manufacture 2030). Consumer health (Kenvue post-spin) and J&J pharma/MedTech continue packaging goals: recyclable, reusable, or compostable design; recycled content; and reduction of virgin plastic. Water stewardship and pharmaceuticals-in-the-environment (API risk assessments, wastewater controls) remain part of environmental disclosure and CDP reporting.
J&J Health for Humanity Report; 23% operational carbon cut; renewable electricity
In 2024, Johnson & Johnson released its Health for Humanity Report, reporting a 23% reduction in operational (Scope 1 & 2) carbon footprint between 2021 and 2023 and 87% of electricity from renewable sources globally. The company's SBTi-validated goals (100% renewable electricity by 2025, 44% emissions cut by 2030, 80% of suppliers with SBTs by 2028) and net zero 2045 ambition framed environmental communications. Packaging, water, and pharmaceuticals-in-the-environment were disclosed; Kenvue (consumer health spin-off) reported separately on its own sustainability targets.
J&J achieves 100% renewable electricity in US, Canada, and Europe
In 2023, Johnson & Johnson announced it had reached 100% renewable electricity for all sites in the United States, Canada, and Europe, ahead of its 2025 global target. The company reported approximately 88% renewable electricity globally and continued progress on Scope 1 & 2 emissions reduction. Kenvue (consumer health) was spun off in August, taking brands such as Listerine, Neutrogena, and Tylenol; J&J retained pharma and MedTech environmental commitments. Packaging, water, and supply chain decarbonisation (Energize, Onward) remained priorities.
J&J SBTi-validated climate goals; renewable electricity and supplier programmes
In 2022, Johnson & Johnson continued to implement its Science Based Targets initiative (SBTi)–validated goals: 100% renewable electricity by 2025, 44% reduction in Scope 1 & 2 emissions by 2030 (2021 baseline), and 80% of suppliers (by spend) with science-based targets by 2028. The company used the CO2 Capital Relief Program (up to $40M annually) for energy efficiency projects and engaged suppliers through Onward and Energize. Consumer health packaging (recyclable design, recycled content) and pharmaceuticals-in-the-environment disclosure remained part of sustainability reporting.
J&J Health for Humanity 2020 Report; new 2025 climate and packaging goals
In 2021, Johnson & Johnson released its 2020 Health for Humanity Report, documenting ESG performance and introducing Health for Humanity 2025 goals. Environmental priorities included decarbonising operations and value chains: 100% renewable electricity by 2025, 44% Scope 1 & 2 reduction by 2030 (2021 baseline), and net zero by 2045. Consumer health reported to the Ellen MacArthur Foundation Global Commitment on plastic packaging (recyclable/reusable/compostable, recycled content). Water stewardship and pharmaceuticals-in-the-environment (API assessments, wastewater) remained in scope.
J&J Healthy Lives Mission; $800M to 2030 for sustainable consumer health packaging
In 2020, Johnson & Johnson Consumer Health launched the Healthy Lives Mission, committing $800 million through 2030 to make consumer health products more sustainable. Targets included 100% recyclable, reusable, or compostable plastic packaging and certified/post-consumer recycled paper by 2025; 15% post-consumer recycled content; and 25% virgin plastic reduction. The company redesigned bottles (recycled plastic, pump removal on baby lotion), switched Listerine caps to clear resin for recyclability, and reduced carton size for Carefree and o.b. Pharma and device divisions reported on fibre-based packaging and hospital recycling programmes.
J&J climate and packaging reporting; carbon and plastic under scrutiny
In 2019, Johnson & Johnson reported on carbon reduction, renewable energy, and packaging in its sustainability and citizenship reporting. The company faced growing investor and NGO pressure on climate disclosure (CDP, TCFD) and on plastic packaging and recyclability. Consumer health (baby care, Listerine, Neutrogena, etc.) and pharma/device packaging were in scope; J&J emphasised design for recyclability and recycled content. Water use and wastewater (including pharmaceuticals-in-the-environment) were part of environmental stewardship. The Health for Humanity 2020 goals were in their final year; new 2025 goals would follow.
J&J environmental goals and carbon; packaging and water stewardship
In 2018, Johnson & Johnson continued to report on carbon emissions, energy efficiency, and renewable electricity under its citizenship and sustainability framework. The company invested in the CO2 Capital Relief Program for site-level energy projects and reported on water use and wastewater treatment at manufacturing facilities. Packaging recyclability and recycled content were part of product sustainability; pharmaceuticals-in-the-environment (API risk assessments since 2006, wastewater controls) were disclosed in position statements. Health for Humanity 2020 goals included environmental metrics alongside access and community.
J&J carbon and energy; CO2 Capital Relief and renewable electricity
In 2017, Johnson & Johnson reported on carbon footprint and energy under Healthy Future 2015 and Health for Humanity 2020. The CO2 Capital Relief Program ($40M annually) funded efficiency and renewable projects at sites; the company had completed 94 of 112 approved energy projects over several years. Renewable electricity and fleet/facility emissions targets were part of environmental disclosure. Water stewardship, wastewater treatment (including API controls at pharma plants), and packaging were reported. J&J participated in CDP and framed environmental performance within its Credo and citizenship narrative.
J&J Paris alignment; carbon and water in citizenship reporting
Following the Paris Agreement (2015), Johnson & Johnson aligned its environmental reporting with climate and resource goals. The company reported on carbon emissions (Scope 1, 2, and elements of 3), water use, and waste at manufacturing sites. Healthy Future 2015 targets (facility carbon, fleet efficiency) and Health for Humanity 2020 framed reporting. Pharmaceuticals-in-the-environment (API risk assessments, wastewater controls) were disclosed. Packaging and recyclability gained attention as plastic and circular economy became investor and NGO priorities. J&J's Janssen Spring House site (Pennsylvania) remained under EPA RCRA corrective action for historical groundwater.
J&J Healthy Future 2015; facility carbon and fleet targets
In 2015, Johnson & Johnson pursued its Healthy Future 2015 citizenship and sustainability goals, including 20% absolute reduction in facility carbon emissions by 2020 (from a 2010 baseline) and 20% improvement in fleet emissions efficiency. The company had already exceeded earlier carbon and waste targets (e.g. 23% carbon reduction from 1990 by 2010). CO2 Capital Relief and on-site renewable/energy projects continued. Water, wastewater (including API controls), and packaging were part of environmental reporting. The Paris Agreement later in the year increased pressure for science-based targets and net-zero ambition.
J&J carbon, water, and waste reporting; EPA corrective action at Janssen site
In 2014, Johnson & Johnson reported on carbon, water, and waste in its citizenship and sustainability reports. The company had exceeded 2010 carbon and waste reduction targets and was working toward Healthy Future 2015 goals. Janssen Research and Development (formerly J&J Pharmaceutical R&D) at Spring House, Pennsylvania, remained in EPA RCRA corrective action for groundwater; the EPA had determined migration was "under control" with long-term monitoring and remediation objectives. Pharmaceuticals-in-the-environment and wastewater controls at manufacturing sites were part of J&J's environmental stewardship narrative.
J&J environmental reporting; Healthy Future 2015 and water stewardship
In 2013, Johnson & Johnson reported on carbon, energy, water, and waste in its citizenship reporting and prepared for the launch of Healthy Future 2015 goals (formalised in 2011). The company had achieved a 23% carbon reduction from 1990 levels by 2010 and continued to invest in the CO2 Capital Relief Program. Water stewardship (chillers, cooling towers, rainwater capture, leak detection) and wastewater treatment at manufacturing sites were disclosed. API environmental risk assessments (since 2006) and supplier environmental performance (EcoVadis, PSCI) were part of J&J's environmental narrative. The Janssen Spring House site remained in EPA corrective action.
J&J carbon and waste targets exceeded; water and energy programmes
In 2012, Johnson & Johnson had exceeded its 2010 carbon target (7% reduction from 1990; achieved 23%) and waste targets (25% reduction in hazardous waste disposed, 12% in non-hazardous). The CO2 Capital Relief Program had approved 112 energy projects (94 completed) with $208M spent over several years. Water stewardship (chillers, HVAC, cooling towers, rainwater capture, leak detection) and minimum secondary wastewater treatment at manufacturing plants were in place. The company was implementing Healthy Future 2015 with facility and fleet goals. API environmental risk assessments and supplier oversight supported pharmaceuticals-in-the-environment commitments.
In 2011, Johnson & Johnson launched "Healthy Future 2015," its citizenship and sustainability goals, including 20% absolute reduction in facility carbon emissions by 2020 (2010 baseline) and 20% improvement in fleet emissions efficiency. The company had already exceeded its 2010 carbon target (23% reduction from 1990). Water, waste, and packaging remained part of environmental reporting; API environmental risk assessments (since 2006) and wastewater controls addressed pharmaceuticals-in-the-environment. The framework set the stage for later Health for Humanity 2020/2025 and SBTi-validated climate goals.
J&J exceeds 2010 carbon target (23% from 1990); waste and water programmes
By 2010, Johnson & Johnson had exceeded its carbon reduction target: 23% reduction from 1990 levels (target was 7%). The company also exceeded waste goals: 25% decrease in hazardous waste disposed and 12% in non-hazardous (2005 baseline). The CO2 Capital Relief Program ($40M annually) supported energy efficiency and renewable projects at sites. Water stewardship (chillers, cooling towers, rainwater capture, leak detection) and wastewater treatment (minimum secondary at manufacturing plants) were in place. API environmental risk assessments had been conducted for new APIs since 2006. The stage was set for Healthy Future 2015 (2011) and later science-based targets.
J&J carbon and energy programmes; CO2 Capital Relief and 2010 targets
In 2009, Johnson & Johnson continued to work toward its 2010 carbon target (7% reduction from 1990) and waste reduction goals through the CO2 Capital Relief Program and site-level energy projects. Water stewardship and wastewater treatment at manufacturing facilities were part of environmental reporting. The company had implemented environmental risk assessments for active pharmaceutical ingredients (APIs) before market approval since 2006. Sustainability reporting (carbon, water, waste) was integrated into citizenship and annual reporting. The following year J&J would exceed its 2010 targets and later launch Healthy Future 2015.
J&J environmental reporting; carbon, water, and API risk assessments
In 2008, Johnson & Johnson reported on carbon emissions, energy, water, and waste in its sustainability and citizenship reporting. The company was on track toward its 2010 carbon reduction target (7% from 1990) and had implemented environmental risk assessments for all new APIs since 2006 to address pharmaceuticals-in-the-environment. Wastewater treatment (minimum secondary) and manufacturing controls (dust collection, closed transfers) were part of environmental stewardship. The CO2 Capital Relief Program funded efficiency projects. Climate and resource use were increasingly framed as corporate responsibility priorities.
J&J sustainability report; carbon 2010 target and API environmental assessments
In 2007, Johnson & Johnson published its sustainability report, reporting progress toward carbon reduction (7% by 2010 from 1990), waste reduction, and water use. The company had introduced environmental risk assessments for active pharmaceutical ingredients (APIs) before market approval in 2006 to address potential impact on aquatic and terrestrial ecosystems. Wastewater treatment and manufacturing controls were part of environmental stewardship. The CO2 Capital Relief Program supported energy projects at sites. J&J's environmental reporting was part of its broader citizenship and Credo narrative; the following decade would bring Healthy Future 2015, Health for Humanity, and science-based climate targets.
J&J portfolio post-Kenvue; pharma and MedTech focus; selective M&A
By 2026, Johnson & Johnson operates as a focused pharmaceutical and medical technology company following the Kenvue consumer health spin-off (2023). No major acquisition or divestment is assumed for the year; M&A is expected to remain selective (bolt-ons, pipeline deals) as J&J prioritises innovation in pharma (Janssen) and devices (DePuy Synthes, J&J Vision). The company retains a minority stake in Kenvue; portfolio discipline and capital allocation to R&D and dividends remain strategic priorities.
J&J one year after Kenvue; pharma and device portfolio; no major M&A
In 2024, Johnson & Johnson operated as a pure-play pharma and MedTech company one year after completing the Kenvue separation. The company retained a minority stake in Kenvue and had no major new acquisition or divestment announced for the year. Portfolio focus remained on innovative medicines (Janssen) and devices (DePuy Synthes, J&J Vision). Selective M&A or licensing could support pipeline and geographic expansion; large transformative deals were not a stated priority. Kenvue continued to trade independently with Tylenol, Listerine, Neutrogena, and other consumer brands.
J&J completes separation of Kenvue; consumer health spin-off
In 2023, Johnson & Johnson completed the separation of its consumer health business into Kenvue Inc. Kenvue's IPO was in May; J&J launched an exchange offer in July and finalised the separation on August 23, 2023. J&J accepted 190.9 million of its own shares in exchange for Kenvue shares, retained a 9.5% equity stake in Kenvue, and secured $13.2 billion in cash from Kenvue's debt offering and IPO. The spin-off allowed J&J to focus on pharmaceuticals and medical devices; Kenvue now owns Tylenol, Listerine, Neutrogena, Aveeno, Johnson's, and other consumer brands.
J&J advances Kenvue spin-off; consumer health separation planned
In 2022, Johnson & Johnson advanced plans to separate its consumer health business into a new publicly traded company (later named Kenvue). The company had announced the intention to spin off consumer health in late 2021; throughout 2022 it prepared for an IPO and separation expected in 2023. The move would leave J&J focused on pharmaceuticals and medical devices; consumer brands (Tylenol, Listerine, Neutrogena, Aveeno, Johnson's, etc.) would become Kenvue. No other major acquisition or divestment was completed in the year.
J&J announces plan to separate consumer health business (Kenvue)
In November 2021, Johnson & Johnson announced its intention to separate the consumer health business into a new, publicly traded company. The spin-off would create a standalone company (later named Kenvue) owning brands such as Tylenol, Listerine, Neutrogena, Aveeno, Johnson's, and Band-Aid, while J&J would focus on pharmaceuticals and medical devices. The transaction was expected to be completed in 18–24 months. No other major acquisition or divestment was completed in 2021; the company continued to integrate prior deals (e.g. Momenta) and manage its three-segment portfolio.
J&J acquires Momenta Pharmaceuticals for approximately $6.5 billion
In August 2020, Johnson & Johnson announced an agreement to acquire Momenta Pharmaceuticals for approximately $6.5 billion in an all-cash tender at $52.50 per share. The acquisition was completed in October 2020. Momenta brought nipocalimab (M281), an anti-FcRn antibody in late-stage development for autoimmune conditions (myasthenia gravis, hemolytic disease of the fetus and newborn, and others). The deal expanded Janssen's leadership in autoimmune diseases and added a Cambridge, Massachusetts, innovation footprint. It was one of the largest pharma acquisitions of the year.
J&J pharma and device portfolio; no major acquisition or divestment
In 2019, Johnson & Johnson did not announce a transformative acquisition or divestment. The company operated three segments: pharmaceuticals (Janssen, including Actelion assets), medical devices (DePuy Synthes, J&J Vision, Ethicon, etc.), and consumer health (Tylenol, Listerine, Neutrogena, Johnson's—later to become Kenvue). Portfolio and pipeline were strengthened through smaller deals or licensing; no blockbuster M&A was completed. The focus was on commercial execution, R&D, and managing litigation (talc, mesh, hip) and quality (consumer health).
J&J portfolio integration; Actelion and Abbott Medical Optics absorbed
In 2018, Johnson & Johnson continued to integrate Actelion (acquired 2017) into Janssen and Abbott Medical Optics (acquired 2017) into J&J Vision. No major new acquisition or divestment was announced. The company's three segments—pharma, medical devices, consumer health—remained intact. Pipeline and device portfolio were supported by licensing and smaller deals. Strategic priorities included growth in oncology, immunology, pulmonary hypertension (Actelion), and eye health (J&J Vision). Consumer health would later be earmarked for separation (Kenvue, 2021–2023).
J&J completes Actelion ($30B) and Abbott Medical Optics ($4.3B) acquisitions
In 2017, Johnson & Johnson completed two major acquisitions. In June, J&J closed the acquisition of Actelion for approximately $30 billion (all-cash at $280 per share). Actelion's drug discovery operations were spun out into Idorsia (J&J retained 16% plus rights); J&J gained Opsumit, Uptravi, Tracleer, and other pulmonary arterial hypertension medicines for Janssen. In February, J&J completed the acquisition of Abbott Medical Optics for $4.325 billion, expanding eye health (cataract, LASIK, consumer) into Johnson & Johnson Vision.
J&J agrees to acquire Abbott Medical Optics for $4.325 billion
In September 2016, Johnson & Johnson announced a definitive agreement to acquire Abbott Medical Optics (AMO) from Abbott for $4.325 billion in cash. AMO had 2015 sales of about $1.1 billion and included ophthalmic products for cataract surgery, laser refractive surgery (LASIK), and consumer eye health. The acquisition would expand J&J's vision business beyond Acuvue contact lenses and create a broader Johnson & Johnson Vision platform. The deal closed in February 2017. No other major acquisition was announced in 2016.
J&J acquires Alios BioPharma for approximately $1.75 billion
In September 2014, Johnson & Johnson announced a definitive agreement to acquire Alios BioPharma, a clinical-stage antiviral company, for approximately $1.75 billion in cash. The acquisition was completed in November 2014. Alios brought a pipeline of antiviral compounds, including AL-8176 (Phase 2 for RSV in infants) and early-stage hepatitis C assets, strengthening Janssen's infectious disease portfolio. Alios became part of the Janssen Pharmaceutical Companies. The deal reflected J&J's focus on viral diseases and specialty pharma. No other major acquisition was completed in 2014.
J&J completes Synthes acquisition for approximately $19.7 billion
On June 14, 2012, Johnson & Johnson completed the acquisition of Synthes, Inc. for approximately $19.7 billion in cash and stock (announced April 2011). Synthes was a leading maker of trauma, spine, and craniomaxillofacial devices (screws, plates, surgical tools, implants). The combination with J&J's DePuy created DePuy Synthes, the world's largest orthopaedics company. The deal had received FTC and European Commission clearance. Synthes founder Hansjörg Wyss had supported the transaction. The acquisition was J&J's largest to date and reshaped its medical device segment.
J&J agrees to acquire Synthes for $21.3 billion; largest deal in company history
On April 27, 2011, Johnson & Johnson announced a definitive agreement to acquire Synthes, Inc., a Swiss-American medical device company, for $21.3 billion (CHF 159 per share in cash and stock)—J&J's largest acquisition ever. Synthes was a leader in trauma, spine, and craniomaxillofacial devices. The combination with DePuy would create the world's largest orthopaedics business. The deal was subject to regulatory approval and was expected to close in the first half of 2012. Founder Hansjörg Wyss agreed to support the transaction. The acquisition closed in June 2012 for a final value of approximately $19.7 billion.
J&J portfolio; Pfizer consumer and Synthes in focus; no major deal closed
In 2010, Johnson & Johnson did not complete a major acquisition or divestment. The company had integrated the Pfizer consumer health business (acquired 2006) and was operating pharmaceuticals (Janssen), medical devices (DePuy, Ethicon, etc.), and consumer health. The DePuy ASR hip recall and McNeil quality crisis dominated the year; M&A was not the headline. J&J would announce the landmark Synthes deal in April 2011. Portfolio and capital allocation remained focused on R&D, dividends, and selective deal-making.
J&J acquires Cougar Biotechnology for approximately $970 million
In 2009, Johnson & Johnson agreed to acquire Cougar Biotechnology, a cancer drug developer, for approximately $970 million in cash ($43 per share, a 16% premium). Cougar was developing abiraterone acetate, an experimental prostate cancer treatment in pivotal trials, as well as candidates for breast cancer and multiple myeloma. The acquisition strengthened Janssen's oncology pipeline. Abiraterone would later be approved as Zytiga and become a blockbuster. The deal reflected J&J's focus on specialty pharma and oncology. No other major acquisition was completed in 2009.
J&J portfolio; Pfizer consumer integrated; no major acquisition or divestment
In 2008, Johnson & Johnson did not announce a transformative acquisition or divestment. The company had fully integrated the Pfizer consumer health business (Listerine, Visine, Neosporin, Zantac, etc.) acquired in 2006. Pharmaceuticals (Janssen), medical devices (DePuy, Ethicon, etc.), and consumer health comprised the three segments. The financial crisis and economic downturn affected capital allocation; J&J maintained its dividend and credit rating. The following years would bring Cougar (2009), Synthes (2011/2012), and eventually Actelion and Abbott Medical Optics.
J&J portfolio; Alza and Pfizer consumer integrated; no major new deal
In 2007, Johnson & Johnson did not complete a blockbuster acquisition or divestment. The company had integrated Alza (acquired 2001; drug delivery, Concerta, Ditropan XL) and the Pfizer consumer health business (acquired 2006; Listerine, Visine, Zantac, etc.). The three-segment structure—pharma, medical devices, consumer health—was well established. J&J continued to pursue licensing and smaller deals. The next decade would bring Cougar (2009), Synthes (2011/2012), Actelion (2017), Abbott Medical Optics (2016/2017), and eventually the Kenvue consumer health separation (2021–2023).
J&J acquires Pfizer consumer health business for $16.6 billion
In June 2006, Johnson & Johnson announced the acquisition of Pfizer's consumer healthcare business for $16.6 billion in cash. The deal included iconic brands such as Listerine, Visine, Neosporin, Lubriderm, Sudafed, Zantac, and Nicorette, with 2005 sales of $3.9 billion. It also gave J&J rights to the OTC version of Zyrtec. The acquisition rebalanced J&J's segments: consumer would represent about 25% of revenue (up from 18%), with pharma and devices at 40% and 35%. The price was among the highest ever for a consumer health business at the time. J&J had earlier lost a bidding war for Guidant to Boston Scientific.
J&J agrees to acquire Alza Corporation for approximately $10.5 billion
On March 27, 2001, Johnson & Johnson announced an agreement to acquire Alza Corporation in a stock-for-stock merger valued at approximately $10.5 billion in net equity. Alza shareholders would receive 0.49 J&J shares per Alza share. Alza brought drug delivery technologies and products including Concerta (ADHD), Ditropan XL (incontinence), and the technology behind Nicoderm. The acquisition strengthened J&J's pharma business (Procrit, Risperdal) and expanded into CNS, pain, and women's health. The deal closed later in 2001; Alza was integrated into Janssen. The acquisition was one of the largest pharma deals of the early 2000s.
Johnson & Johnson acquisitions and portfolio at the turn of the millennium
By 2000, Johnson & Johnson was one of the world's largest healthcare companies with three segments: pharmaceuticals (Janssen, Centocor, and others), medical devices (DePuy, Ethicon, Cordis, J&J Vision/Acuvue), and consumer health (Tylenol, Motrin, Band-Aid, Johnson's, Neutrogena). The company had a long history of acquisitions (e.g. Janssen, Centocor, Neutrogena). The following decade would bring the landmark Alza (2001), Pfizer consumer (2006), Synthes (2011/2012), Actelion (2017), and Kenvue consumer health separation (2023)—making M&A and portfolio strategy a defining part of J&J's modern history.
